Breast Cancer Research and Treatment

, Volume 133, Issue 2, pp 501–510

Vascular proliferation is a prognostic factor in breast cancer

  • Jarle B. Arnes
  • Ingunn M. Stefansson
  • Oddbjørn Straume
  • Jan P. Baak
  • Per E. Lønning
  • William D. Foulkes
  • Lars A. Akslen
Preclinical Study

DOI: 10.1007/s10549-011-1785-7

Cite this article as:
Arnes, J.B., Stefansson, I.M., Straume, O. et al. Breast Cancer Res Treat (2012) 133: 501. doi:10.1007/s10549-011-1785-7

Abstract

Angiogenesis is important for the growth and spread of malignant tumors, and anti-angiogenesis treatment is currently being evaluated for breast cancer and other tumors. Although microvessel density is the most commonly used tissue-based marker of tumor associated angiogenesis, it has significant limitations and has not proven effective as a predictive factor in selecting patients for treatment. We here wanted to explore the significance of vascular endothelial cell proliferation in breast carcinoma. We examined microvessel proliferation in breast cancer by dual immunohistochemical staining, using the pan-endothelial marker Factor-VIII combined with proliferation of endothelial cells by Ki-67 expression, in three independent series of breast cancer, including a total of 499 patients and 141 events during follow-up. Common statistical tests of associations as well as univariate and multivariate regression analysis of patient survival were used. By counting vessels with actively proliferating endothelium, we show that microvascular proliferation is a significant predictor of disease progression in breast cancer, especially among high-grade and ER-negative tumors. Our findings indicate that this novel marker of active tumor angiogenesis might be of value in patient management and should be further studied in the context of patient selection for anti-angiogenesis treatment.

Keywords

Breast cancer Angiogenesis Vascular proliferation Prognosis 

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Jarle B. Arnes
    • 1
  • Ingunn M. Stefansson
    • 1
  • Oddbjørn Straume
    • 1
  • Jan P. Baak
    • 2
    • 3
    • 4
  • Per E. Lønning
    • 5
    • 6
  • William D. Foulkes
    • 7
    • 8
    • 9
    • 10
  • Lars A. Akslen
    • 1
  1. 1.Section for Pathology, The Gade InstituteUniversity of Bergen, Haukeland University HospitalBergenNorway
  2. 2.Department of PathologyStavanger University HospitalStavangerNorway
  3. 3.The Gade InstituteUniversity of BergenBergenNorway
  4. 4.Free UniversityAmsterdamThe Netherlands
  5. 5.Section of Oncology, Institute of MedicineUniversity of BergenBergenNorway
  6. 6.Department of OncologyHaukeland University HospitalBergenNorway
  7. 7.Hôpital du Sacré-Coeur de MontréalMontréalCanada
  8. 8.Program in Cancer Genetics, Departments of Oncology and Human GeneticsMcGill UniversityMontréalCanada
  9. 9.Segal Cancer CentreJewish General HospitalMontréalCanada
  10. 10.McGill UniversityMontréalCanada

Personalised recommendations